Pharmaceutical giant GlaxoSmithKline has invested $300 million into home DNA testing company 23andMe, allowing it to develop drugs based on human genetics.
The four-year agreement allows GSK access to 23andMe’s vast database to accelerate its drug research and development work.
More than 5 million customers use 23andMe’s saliva kit to profile their genes. The kits allow users to uncover insights about their ancestry, other people who share your DNA, as well as discover how much of your DNA is Neanderthal.
“We are excited about this unique collaboration as we know that drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines,” Hal Barron, GSK’s Chief Scientific Officer and president R&D, said in a statement. Read more…
Read more: mashable.com